UBS analyst Colin Bristow downgraded Pfizer to Neutral from Buy with a price target of $47, down from $55. COVID estimates for Pfizer still need to come down and the company’s pipeline upside is minimal in the near- to mid-term, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE:
